Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Cyclophosphamide (XC) vs Physician's Choice as Maintenance Therapy for Advanced Breast Cancer
NCT05876065Recruiting
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Randomised, open-label trial of capecitabine and cyclophosphamide in breast cancer (2 arms). Primary endpoint: Progression-Free Survival at 1 year. Started Jun 2023; status: recruiting.
02
Drugs
capecitabinecyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05876065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876065.